Rheumatoid Arthritis-Associated Interstitial Lung Disease
Conditions
Brief summary
Evaluation of serum KL6 level in rheumatoid arthritis-associated interstitial lung disease (RA-ILD).
Detailed description
Rheumatoid arthritis (RA) is one of the most common connective tissue diseases (CTD). Its prevalence is increasing worldwide . It is responsible for a considerable number of hospital visits in Egyptian Hospitals . Pumlonary involvement is common in rheumatoid arthritis (RA). Interstitial lung disease associated rheumatoid arthritis (ILD-RA) is responsible for significant morbidity and mortality . Krebs von den Lungen 6 (KL-6) is a mucin like glycoprotein that is found mainly on the surface of type II pneumocytes as well as in bronchiolar epithelial cells . It has chemotactic and anti-apoptotic action on fibroblasts , hence, it is considered as a marker of pulmonary epithelial cell injury . Krebs von den Lungen-6 (KL6) has been found to be a valuable diagnostic tool in many interstitial lung diseases. KL6 was found to be a valuable prognostic marker, as well as a marker for disease severity in idiopathic pulmonary fibrosis (IPF) . KL6 was found useful as well in predicting in-hospital mortality in patients with Acute exacerbation of interstitial lung disease (AE-ILD) . KL-6 serum level can serve as a diagnostic marker for connective tissue disease-associated interstitial lung disease (CTD-ILD). It can be used to monitor effectiveness of medical treatment and patient response to pulse therapy . Its value in Rheumatoid Arthritis-associated Interstitial Lung Disease (RA-ILD) has not yet been adequately investigated.
Interventions
KL-6 concentration will be measured using Sandwich ELISA technique (SinoGene Clone Biotech, China).
Sponsors
Study design
Eligibility
Inclusion criteria
Diagnosis of RA will be based on American College of Rheumatology/European League against Rheumatism (ACR-EULAR) classification criteria 2010. Inclusion Criteria: * all patients have rheumatoid arthritis-associated interstitial lung disease
Exclusion criteria
* Patients with any evidence of infection will be excluded.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| KL-6 | one day | detect its serum level |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Spirometry | one day | FEV1, FVC, FVC/FEV1 will be measured. |
| HRCT chest | one day | It will be will be assessed by the radiologist to determine pulmonary involvement. |
Countries
Egypt